FDA Approved: ASTAGRAF XL — Supplemental Application (Astellas Pharma US, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ASTAGRAF XL (tacrolimus extended-release capsules) from Astellas Pharma US, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplant Rejection
• Kidney Transplant Rejection
• Liver Transplant Rejection

Drugs mentioned

• Astagraf XL (Tacrolimus)

Snippet

SUPPL AP for ASTAGRAF XL (TACROLIMUS EXTENDED-RELEASE CAPSULES)